Keith Wilson said:Quick question if anyone knows how this actually works. Did the folks over at Sony Music run any actual tests on small American groups—like what kind of sample size or methodology were they using? Or did they just shuffle some paperwork around, mix a few test tubes together, and decide it was good enough to pass?
Thanks.
I have some information here—not regarding Sony Music, specifically, but regarding the trials Pfizer used to get authorization from the FDA.
https://www.pfizer.com/news/press-re...esults-pivotal
https://www.fda.gov/news-events/pres...-emergency-use
Based on what I’m seeing above, this vaccine was authorized for emergency use (meaning it wasn't fully approved, just cleared for an emergency rollout) based on a clinical trial that only included 1,131 children in the experimental group. To put that into perspective: if this vaccine hypothetically carried a mortality risk of 1 in 2,000, a trial of that size would have a 43% chance of failing to detect it. And yet, based on a study that small, we are vaccinating hundreds of thousands of children against a disease that poses almost zero statistical threat to them.
Fortunately, I don't have kids in that age bracket, but the whole logic seems fundamentally broken to me. Why expose children to an experimental vaccine when the disease itself poses virtually no danger to them? The argument is always: "But they can spread it." To whom? From what I can see, either other children or adults. Other children aren't at risk, and adults can just get vaccinated themselves. That leaves only the vulnerable adults who, for various health reasons, cannot be vaccinated. So, the conclusion is that we should expose the entire pediatric population to the risks of an experimental shot just to protect a negligible number of adults who are already medically compromised. Someone put it well: we adults are here to protect the children, not the other way around.